Vertex lavishes $80M cash to expand gene therapy tool kit; Supernus bags a $300M CNS portfolio
→ Vertex’s bullish outlook wasn’t just manifested in its upbeat revision of the full-year guidance. Earlier this week, the Boston biotech handed over
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
